Trial Profile
A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Gatipotuzumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Glycotope
- 20 Oct 2020 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 This study has been discontinued in UK (End date: 28 Jul 2017) as per European Clinical Trials Database record.
- 24 Oct 2017 This study has been completed in Spain as per Eudra.